

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**

(19) World Intellectual Property Organization  
International Bureau




(43) International Publication Date  
7 June 2001 (07.06.2001)

PCT

(10) International Publication Number  
**WO 01/40166 A1**

- (51) International Patent Classification<sup>7</sup>: C07C 271/28, A61K 31/325, A61P 5/48, 3/00
- (74) Agent: GLOBAL INTELLECTUAL PROPERTY; AstraZeneca AB, S-151 85 Södertälje (SE).
- (21) International Application Number: PCT/SE00/02380
- (22) International Filing Date:  
29 November 2000 (29.11.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
9904412-5 3 December 1999 (03.12.1999) SE
- (71) Applicant (for all designated States except US): ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): HALLGREN, Agneta [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). ROOS, Kristina [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMMINUTED FORM OF 3-{4-[2-(4-*TERT*-BUTOXYCARBONYLAMINOPHENYL)ETHOXY]PHENYL}-(S)-2-ETHOXY PROPANOIC




(57) Abstract: The present invention relates to a reduced particle size form of the compound 3-{4-[2-(4-*tert*-butoxycarbonylamino)phenyl]ethoxy}phenyl-(S)-2-ethoxy propanoic acid, as shown in formula (I), or a pharmaceutically acceptable salt thereof or a solvate of either thereof. The invention also concerns methods of treating one or more conditions associated with Insulin Resistance Syndrome using the reduced particle size form of the compound, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in one or more of said conditions. The invention further concerns pharmaceutical compositions containing the reduced particle size form of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient, as well as processes for the manufacture of the reduced particle size form of the compound, or a pharmaceutically acceptable salt thereof.

WO 01/40166 A1

Comminuted form of 3-{4-[2-(4-*tert*-butoxycarbonylamino)phenyl]ethoxy}phenyl}-(S)-2-ethoxy propanoic acid

The present invention relates to a reduced particle size form of the compound 3-{4-[2-(4-*tert*-butoxycarbonylamino)phenyl]ethoxy}phenyl}-(S)-2-ethoxy propanoic acid, as shown in formula I below,



or a pharmaceutically acceptable salt thereof or a solvate or either thereof. The invention also concerns methods of treating one or more conditions associated with Insulin Resistance Syndrome using the reduced particle size form of the compound, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in one or more of said conditions. The invention further concerns pharmaceutical compositions containing the reduced particle size form of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient, as well as processes for the manufacture of the reduced particle size form of the compound, or a pharmaceutically acceptable salt thereof.

In the formulation of drug compositions, it is important for the drug substance to be in a form in which it can be conveniently handled and processed. This is of importance from the point of view of manufacture of pharmaceutical formulations comprising the active compound.

The above compound is useful in treating metabolic disorders, such as, Insulin Resistance Syndrome (IRS), defined as reduced sensitivity to the actions of insulin in the whole body or individual tissues such as skeletal muscle, myocardium, fat and liver prevail in many individuals with or without diabetes mellitus. IRS refers to a cluster of manifestations including insulin resistance with accompanying hyperinsulinemia, possibly type II diabetes mellitus, arterial hypertension, central (visceral) obesity, dyslipidemia observed as deranged lipoprotein levels typically characterised by elevated VLDL (very low density lipoproteins) and reduced HDL (high density lipoproteins) concentrations and reduced fibrinolysis.


- 2 -

Recent epidemiological research has documented that individuals with insulin resistance run a greatly increased risk of cardiovascular morbidity and mortality, notably suffering from myocardial infarction and stroke. In type II diabetes mellitus these atherosclerosis related conditions cause up to 80% of all deaths.

5 In clinical medicine there awareness of the need to increase the insulin sensitivity in IRS and thus to correct the dyslipidemia which is considered to cause the accelerated progress of atherosclerosis. However this is not a universally defined disease.

We have discovered a reduced particle size form of the compound described above. This provides a basis for the present invention. Significant advantages can arise when  
10 the compound of formula I is in a reduced particle size form, for example, in the performance of the compound when it is manufactured so as to achieve uniform formulations with an even loading of active ingredient within as well as between batches. In addition reductions in particle size are typically associated with increased dissolution rates when administered orally and improved oral bioavailability, when oral bioavailability is limited by the dissolution rate  
15 of the active ingredient.

Accordingly provided in the present invention is a reduced particle size form of (S)-2-ethoxy-3-{4-[2-(4-*tert*-butoxycarbonylamino)phenyl]ethoxy}phenyl}-(S)-2-ethoxy propanoic acid, as shown in formula I below



20

or a pharmaceutically-acceptable salt or a solvate or either thereof.

By the use of the term "reduced particle size" we refer to solid Compound 1, or a pharmaceutically-acceptable salt thereof, or a solvate of either thereof, reduced by suitable processing techniques to a solid of smaller particle size and, consequently, greater surface  
25 area. Any number of processing techniques known in the pharmaceutical field may be used to reduce solid particle size, such as grinding, milling and micronising, reference should be made to Remington: The Science and Practise of Pharmacy, 19<sup>th</sup> Ed., pages 1598-1602, for a more

By use of the term "solvated" we include hydrated.

Accordingly presented as a further feature of the invention is a process for the preparation of a reduced particle size form of the compound of formula I, or a  
5 pharmaceutically-acceptable salt or a solvate of either thereof, comprising comminuting a solid form of the compound of formula I, or a pharmaceutically-acceptable salt or a solvate of either thereof, for a sufficient period until the desired size of particle of the compound of formula I, or a pharmaceutically-acceptable salt or a solvate of either thereof, is generated.

The range of particle sizes preferred in this invention start from, in increasing  
10 preference, moderately fine powder, fine powder, very fine powder, microfine powder to, most preferably, superfine powder.

The above references to particle sizes are taken from the British Pharmacopoeia 1993, Volume II, Appendix XVII B, A193, and are reproduced below for reference.

15 Moderately fine powder

A powder all the particles of which pass through a sieve with a nominal mesh aperture of 355 $\mu$ m and not more than 40.0% by weight pass through a sieve with a nominal mesh aperture of 250 $\mu$ m.

20 Fine powder

A powder all the particles of which pass through a sieve with a nominal mesh aperture of 180 $\mu$ m and not more than 40.0% by weight pass through a sieve with a nominal mesh aperture of 125 $\mu$ m.

25 Very fine powder

A powder all the particles of which pass through a sieve with a nominal mesh aperture of 125 $\mu$ m and not more than 40.0% by weight pass through a sieve with a nominal mesh aperture of 45 $\mu$ m.

Microfine powder

A powder of which not less than 90% by weight of the particles pass through a sieve with a nominal mesh aperture of 45 $\mu$ m.

Superfine powder

5 A powder of which not less than 90% by weight of the particles pass through a sieve with a nominal mesh aperture of 10 $\mu$ m.

The particular sieves to be used in determining the particle size are described in British Pharmacopoeia 1993 Volume II, Appendix XVIIIB, A193-A194, which part is incorporated herein by reference.

10 A feature of the invention is a reduced particle size form of a compound of formula I, as described above, for use in medical therapy.

According to a further feature of the invention there is provided a pharmaceutical composition which comprises a reduced particle size form of a compound of formula I, as described above, in association with a pharmaceutically-acceptable diluent, adjuvant or  
15 carrier.

The composition may be in a form suitable for oral use, for example a tablet, capsule, aqueous or oily solution, suspension or emulsion; for topical use, for example a cream, ointment, gel or aqueous or oily solution or suspension; for nasal use, for example a snuff, nasal spray or nasal drops; for vaginal or rectal use, for example a suppository; for  
20 administration by inhalation, for example as a finely divided powder such as a dry powder or a liquid aerosol; for sub-lingual or buccal use, for example a tablet or capsule; or for parenteral use (including intravenous, subcutaneous, intramuscular, intravascular or infusion), for example a sterile aqueous or oily solution or suspension. In general the above compositions may be prepared in a conventional manner using conventional excipients.

25 The amount of the reduced particle size form of a compound of formula I, as described, above that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.01 mg to 50mg of active agent compounded with an  
30 appropriate and convenient amount of excipient(s) which may vary from about 20 to about

- 5 -

99.99 percent by weight of the total composition. Dosage unit forms will generally contain about 0.0001 mg to about 1 mg of an active ingredient.

The invention also includes the use of a Compound of the invention, as described above in the production of a medicament for use in:-

- 5 (i) treating dyslipidaemia;
- (ii) treating type II diabetes mellitus;
- (iii) treating hyperlipidaemia
- (iv) treating hyperglycaemia;
- (v) treating hyperinsulinaemia;
- 10 (vi) treating arterial hypertension; and/or
- (vii) treating abdominal obesity.

The invention also includes a method of producing an effect as defined hereinbefore or treating a disease or disorder as defined hereinbefore which comprises administering to a warm-blooded animal requiring such treatment an effective amount of a  
15 reduced particle size form of a Compound of formula I, as described above.

The size of the dose for therapeutic or prophylactic purposes of a reduced particle size form of a Compound of the invention, as described above, will naturally vary according to the nature and severity of the medical condition, the age and sex of the animal or patient being treated and the route of administration, according to well known principles of medicine.  
20 Suitable daily doses of the compounds of the invention in therapeutical treatment of humans are about 0.001-10 mg/kg body weight, preferably 0.01-1 mg/kg body weight.

The comminuted form of the compound of formula I may be administered as a sole therapy or they may be administered in conjunction with other pharmacologically active agents such as a anti-diabetic, anti-hypertensive, diuretic or anti-hyperlipidemic agent.

25 The invention will now be illustrated in the following non-limiting Examples.

### Example 1

Synthesis of 3-[4-[2-(4-*tert*-Butoxycarbonylamino)phenyl]ethoxy]phenyl]-(S)-2-ethoxy propanoic acid

Ethyl 3-[4-[2-(4-*tert*-butoxycarbonylamino)phenyl]ethoxy]phenyl]-(S)-2-ethoxy

#### 5 propanoate

Ethyl (S)-2-ethoxy-3-(4-hydroxyphenyl)-propanoate (250g, 1.05 mol, 1.0 eq) was dissolved in dimethylsulfoxide (DMSO) (1000 ml). When a homogenous solution was formed, NaOH (s), beads, 20-40 mesh (48.2 g, 1.21 mol, 1.15 eq) was added. 1-(4-Methyl)phenylsulfonyloxy-2-[(4-*tert*-butoxycarbonylamino)phenyl]ethane (431 g, 1.10 mol, 10 1.05 eq) was dissolved in DMSO (1000 ml). The DMSO solution of 1-(4-methyl)phenylsulphonyloxy-2-[4-(*tert*-butoxycarbonylamino)phenyl]ethane was then added over 10 minutes at 20-25 °C to the solution of ethyl (S)-2-ethoxy-3-(4-hydroxyphenyl)-propanoate. The reaction mixture was then stirred for 1 hour. To fully convert ethyl (S)-2-ethoxy-3-(4-hydroxyphenyl)-propanoate to ethyl 3-[4-[2-(4-*tert*-

15 butoxycarbonylamino)phenyl]ethoxy]phenyl]-(S)-2-ethoxy propanoate an additional amount of 1-(4-methyl)phenylsulfonyloxy-2-[(4-*tert*-butoxycarbonylamino)phenyl] ethane (20 g, 0.05 mol, 0,05 eq) and NaOH (s), beads, 20-40 mesh (2.1 g, 0,05 mol, 0.05 eq) was added. The reaction mixture was stirred for another 3 hours. The mantle was then cooled to 10°C.

3-[4-[2-(4-*tert*-Butoxycarbonylamino)phenyl]ethoxy]phenyl]-(S)-2-ethoxy propanoic acid

20 NaOH (aq) 1M (1.15 l, 1.15 mol, 1.15 eq) was added to a solution of ethyl 3-[4-[2-(4-*tert*-butoxycarbonylamino)phenyl]ethoxy]phenyl]-(S)-2-ethoxy propanoate over 30 minutes at 19-23 °C. Stirring was continued for 1 hour, and then H<sub>2</sub>O (4000 ml) was then added. The water layer was washed with methyl *tert*-butylether (3×2000 ml). The water layer was then acidified to pH 3 with KHSO<sub>4</sub> (aq) 1M (1.6 L, 1.6 mol, 1.6 eq). The acidic water solution was

25 then extracted with ethylacetate (3×2000 ml). The ethylacetate-parts were put together and washed with H<sub>2</sub>O (4×2000 ml). The ethylacetate solution was dried with MgSO<sub>4</sub> (90 g). The salts were filtered off and washed with ethylacetate (3×100 ml). The filtrate was evaporated to dryness. The oil residue (750 g) was dissolved in toluene (1750 ml). The solution was seeded with 3-[4-[2-(4-*tert*-butoxycarbonylamino)phenyl]ethoxy]phenyl]-(S)-2-ethoxy propanoic acid

30 and the crystallisation was continued for 30 minutes. Then isooctane (3500 ml) was added.



toluene:isooctane 1:2 (400 ml) followed by water (300 ml). Drying at 40°C at reduced pressure yielded 382 g (0.89 mol) of

3-[4-[2-(4-*tert*-butoxycarbonylaminophenyl)ethoxy]phenyl]-(S)-2-ethoxy propanoic acid as a white powder.

## 5 Example 2

### Preparation of Reduced Particle Size Form of Example 1 by Micronisation

Screw feeder: KTron T20

Jet mill: Titanitride coated steel inside equipment with classifier.

Mill ring: Area of jet hole 1.8 mm<sup>2</sup> (100% ring)

## 10 Humidity: The relative humidity should not exceed 35%

The micronised compound is collected in a 25L-aluminium can, first cleaned with ethanol and dried.

The mill is connected to nitrogen gas. The filter stocking is connected to the nitrogen gas discharge. The aluminium can is connected to the other end of the filter stocking to collect

## 15 the fine fraction of compound.

The compound is charged to the screw feeder so that the lower part of the screw feeder is filled.

### Volumetric screw feeder:

The charging rate should be set at 67±5 g/min (4 kg/h) using a balance and a timer.

## 20 The amount of discharged compound should be controlled over at least one minute. The discharged compound is collected in a stainless steel vessel and recharged to the screw feeder.

### Gravimetric screw feeder:

## 25 Set the charging rate to 67±5 g/min (4 kg/h). Discharge the compound until the right flow has been achieved. The discharged substance is collected in a stainless steel vessel and recharged to the screw feeder.

A tarred aluminium can is placed under or beside the cyclone. A stainless steel vessel is placed under the cyclone. A plastic bag is connected at the cyclone to guide the compound down to the vessel and into the aluminium can.

## 30 The milling pressure at the pipe is set so that a pressure of 5.7±0.3 bar is achieved in the outer chamber.


- 8 -

The ejector pressure is set so that the same pressure is achieved for the ejector pipe pressure as for the milling pipe pressure.

The compound collected during the first 20 seconds of micronisation is collected in the stainless steel vessel. After the first 20 seconds the compound is collected in the aluminium can. All the material that leaves the mill when the screw feeder is turned off should be collected in the stainless steel vessel. Both the material collected at the start and the finish of the micronisation should be discarded.

CLAIMS

1. A reduced particle size form of either  
3-{4-[2-(4-*tert*-butoxycarbonylaminophenyl)ethoxy]phenyl}-(S)-2-ethoxy propanoic acid, as  
5 shown in formula I below,



- or a pharmaceutically-acceptable salt thereof or a solvate of either thereof.
2. A reduced particle size form as claimed in claim 1 which is a superfine powder.
- 10 3. A reduced particle size form as claimed in claim 1 which is a microfine powder.
4. A reduced particle size form as claimed in claim 1 which is a very fine powder.
5. Use of any substance defined in any one of claims 1 to 4 in medical therapy.
6. A pharmaceutical composition comprising a substance as defined in any claim from 1 to 4 in association with a pharmaceutically-acceptable diluent, adjuvant or carrier.
- 15 7. The use of a substance as defined in any claim from 1 to 4 in the production of a medicament for use treating a metabolic disorder.
8. A method for treatment or prophylaxis of conditions associated with reduced sensitivity to insulin, which method comprises administering a therapeutically effective amount of a compound according to any one of claims 1 to 6 to a patient having such reduced  
20 sensitivity to insulin.
9. A method for treatment or prophylaxis of dyslipidaemia, type II diabetes mellitus, hyperglycaemia, hyperinsulinaemia, arterial hypertension and/or abdominal obesity, which method comprises administering a therapeutically effective amount of a compound according to any one of claims 1 to 6 to a patient in need of such treatment or prophylaxis.
- 25 10. A process for the preparation of a compound according to any one of claims 1 to 6, comprising crystallising a compound shown by the formula I, or a salt or solvate thereof, or a solvate of such as salt.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 00/02380

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07C 271/28, A61K 31/325, A61P 5/48, A61P 3/00  
 According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07C, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO 9962870 A1 (ASTRA AKTIEBOLAG), 9 December 1999 (09.12.99), page 4; page 20, line 25 - page 21, line 15, the claims --	1-10
P,A	WO 9962871 A1 (ASTRA AKTIEBOLAG), 9 December 1999 (09.12.99), claims 1, 32, 33 -- -----	1-10

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

12 March 2001

16-03-2001

# INTERNATIONAL SEARCH REPORT

International application No. ....  
PCT/SE00/02380

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 8, 9  
because they relate to subject matter not required to be searched by this Authority, namely:  
**see next sheet**
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SE00/02380

Claims 8, 9 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members


25/02/01

International application No.  
PCT/SE 00/02380

Patent document cited in search report			Publication date	Patent family member(s)			Publication date
WO	9962870	A1	09/12/99	AU	1182299	A	31/05/99
				AU	4667099	A	20/12/99
				AU	4667299	A	20/12/99
				BR	9813192	A	29/08/00
				EP	1029424	A	23/08/00
				NO	20006114	D	00/00/00
				NO	20006116	D	00/00/00
				SE	9801990	D	00/00/00
				WO	9962871	A	09/12/99
WO	9962871	A1	09/12/99	AU	1182299	A	31/05/99
				AU	4667099	A	20/12/99
				AU	4667299	A	20/12/99
				BR	9813192	A	29/08/00
				EP	1029424	A	23/08/00
				NO	20006114	D	00/00/00
				NO	20006116	D	00/00/00
				SE	9801990	D	00/00/00
				WO	9962870	A	09/12/99
				AU	1058399	A	24/05/99
				EP	1027769	A	16/08/00
				SE	9801991	D	00/00/00
				AU	1182399	A	31/05/99
				AU	4667199	A	20/12/99
				NO	20006115	D	00/00/00
				SE	9801992	D	00/00/00
				WO	9962872	A	09/12/99

**Microparticles of 3-{4-[2-(4-tert-butoxycarbonylamino)phenyl]ethoxy]phenyl}-(S)-2-ethoxy propanoic acid - useful for the treatment of e.g. metabolic disorders, insulin resistance syndrome, dyslipidaemia, hyperglycemia and arterial hypertension.**

**Drug Activity:** Microparticle; Powder; Antidiabetic; Antilipemic; Hypotensive; Anorectic  
**Mechanism of Action:** Hypoglycemic



**Use:** As a microparticle or powder for the treatment of metabolic disorders, insulin resistance syndrome, reduced sensitivity to insulin, dyslipidaemia, type 2 diabetes mellitus, hyperglycemia, hyperinsulinaemia, arterial hypertension and abdominal obesity (claimed).

**Dosage:** 0.001 - 50 mg orally. Administration is also topical, vaginal, rectal, parenteral, sublingual, buccal, intravenous, subcutaneous, intramuscular or by inhalation or infusion.

**Advantage:** None given.

**Example:** Micronised (I) is collected in a 25L-aluminium can, first cleaned with ethanol and dried. The mill is connected to nitrogen gas. The filter stocking is connected to the nitrogen gas discharge. The aluminium can is connected to the other end of the filter stocking to collect the fine fraction of (I). (I) is charged to the screw feeder so that the lower part of the screw feeder is filled (example 2).

**Chemistry:** A reduced particle size form of 3-{4-[2-(4-tert-butoxycarbonylamino)phenyl]ethoxy]phenyl}-(S)-2-ethoxy propanoic acid (I) or a salt or solvate of (I) are claimed.

14 pages

Drawings 0/0

**Authors:** Hallgren A; Roos K  
**Publication Date:** 07 June 2001  
**Language:** English  
**Priority:** 03 December 1999 SE-001412

**Location:** Sodertalje, Sweden  
**Document Number:** WO200140166-A1  
**Filed:** 29 November 2000 as SE2380  
**Designated States:** Regional: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE (ARIPO) (Eurasian) (OAPI) National: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

WO 2001 00166